• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    1/7/21 8:00:00 AM ET
    $TRIL
    $PHAT
    $RCKT
    $PASG
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRIL alert in real time by email

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.

    Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.

    Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.

    Max Nowicki, M.D., joined the Frazier Life Sciences team in 2019 and focuses on identifying new public and private investment opportunities. He has been involved in numerous Frazier investments, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Trillium Therapeutics (NASDAQ: TRIL).

    “We are thrilled to announce the promotions of Aditya, Anna, and Max,” said James Topper, Managing Partner at Frazier. “They are extremely valuable members of our team, and are instrumental in helping us create new companies, as well as invest in new public and private companies.”

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

    For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

    Get the next $TRIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIL
    $PHAT
    $RCKT
    $PASG

    CompanyDatePrice TargetRatingAnalyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    3/12/2025$50.00Outperform
    BMO Capital Markets
    Phathom Pharmaceuticals Inc.
    $PHAT
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    Rocket Pharmaceuticals Inc.
    $RCKT
    12/30/2024$32.00Outperform
    Wedbush
    Rocket Pharmaceuticals Inc.
    $RCKT
    12/18/2024$29.00Buy
    Jefferies
    Passage Bio Inc.
    $PASG
    11/29/2024$3.00 → $4.00Outperform
    Wedbush
    Rocket Pharmaceuticals Inc.
    $RCKT
    10/16/2024Sector Outperform
    Scotiabank
    Passage Bio Inc.
    $PASG
    9/3/2024$7.00Buy
    Rodman & Renshaw
    Phathom Pharmaceuticals Inc.
    $PHAT
    5/3/2024$24.00Buy
    Stifel
    More analyst ratings

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

      Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA. Details for the oral presentation of the abstract at ASGCT are as follows: Title: Preliminary Data from a Phase I Gene Therapy Trial of RP-A601 (AAVrh.74-PKP2a) for Adult Pati

      5/9/25 4:30:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      Phase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025 Initial data from the Phase 1 study of RP-A601 for PKP2-ACM anticipated May 2025 IND submission for BAG3-DCM program expected mid-year 2025 Sarbani Chaudhuri appointed Chief Commercial & Medical Affairs Officer Cash, cash equivalents and investments of approximately $318.2M; expected operational runway into the fourth quarter of 2026 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the f

      5/8/25 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parikh Asit bought $24,984 worth of shares (10,000 units at $2.50), increasing direct ownership by 12% to 95,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/8/25 5:27:00 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Breedlove Robert Charles claimed ownership of 55,192 shares (SEC Form 3)

      3 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/6/25 4:59:33 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Orbimed Advisors Llc sold $78,731 worth of shares (235,572 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/24/25 5:38:49 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Financials

    Live finance-specific insights

    See more
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

      • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recordi

      4/23/25 8:00:22 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since last earnings reportPhase 2 EoE trial for VOQUEZNA nearing initiation, with first patient enrollment planned for Q2 2025Management to host conference call today, March 6, 2025, at 8:30 a.m. ET FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointesti

      3/6/25 8:00:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

      SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      12/16/24 7:51:51 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Passage Bio Inc.

      SC 13G - Passage BIO, Inc. (0001787297) (Subject)

      11/14/24 12:03:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      11/8/24 10:52:38 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    SEC Filings

    See more
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      5/8/25 4:12:48 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rocket Pharmaceuticals Inc.

      10-Q - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      5/8/25 4:02:22 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

      SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      5/7/25 10:02:21 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on Rocket Pharmaceuticals with a new price target

      BMO Capital Markets initiated coverage of Rocket Pharmaceuticals with a rating of Outperform and set a new price target of $50.00

      3/12/25 7:31:47 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Phathom Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00

      2/14/25 7:06:18 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Rocket Pharmaceuticals with a new price target

      Wedbush initiated coverage of Rocket Pharmaceuticals with a rating of Outperform and set a new price target of $32.00

      12/30/24 7:26:29 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

      Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      7/18/24 10:52:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      5/11/22 10:51:07 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/11/22 10:17:03 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parikh Asit bought $24,984 worth of shares (10,000 units at $2.50), increasing direct ownership by 12% to 95,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/8/25 5:27:00 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Shah Gaurav bought $101,600 worth of shares (20,000 units at $5.08), increasing direct ownership by 3% to 792,680 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/14/25 6:57:31 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Patel Kinnari bought $99,165 worth of shares (21,099 units at $4.70) (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/10/25 4:07:53 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care